This suggests that, as in other cancer cell contexts, Gmnn inhibition can elicit some effects regardless of TP53 status, such that Gmnn-directed therapeutics could potentially have similar efficacy in both TP53+ and TP53-forms of medulloblastoma. The gene discussed is GMNN; the disease is medulloblastoma.